Shared on 16 Nov 25
Fair value Increased 30%ZYXI: Net Profit Margin Is Expected To Improve Despite Filing Delay
Analysts have raised their fair value price target for Zynex from $2.85 to $3.70 per share. They cite revised assumptions about higher profitability and updated discount rates, even though they expect slightly weaker revenue growth.
Shared on 04 Aug 25
Fair value Decreased 48%The sharp decline in Zynex’s price target is primarily driven by a shift from modest revenue growth to contraction alongside a higher discount rate, resulting in a revised fair value of $2.85. What's in the News Steven Dyson appointed CEO, succeeding Thomas Sandgaard, who will continue as Chairman and Chair of the Technology Committee; Dyson brings over 25 years’ experience in medical technology and private equity.
Shared on 23 Apr 25
Fair value Increased 18%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 37%AnalystConsensusTarget has decreased future PE multiple from 24.1x to 15.1x.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 5.45%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 14%AnalystConsensusTarget has decreased revenue growth from 19.5% to 1.4%, increased profit margin from 10.6% to 13.0%, increased future PE multiple from 19.7x to 23.5x and increased discount rate from 7.4% to 8.4%.
Shared on 11 Mar 25
Fair value Increased 213%AnalystConsensusTarget made no meaningful changes to valuation assumptions.